Ozempic in India: Price, Dose & Weight Loss

Ozempic and Wegovy contain the same molecule — semaglutide, a GLP-1 receptor agonist that mimics a gut hormone to blunt appetite, slow stomach emptying and steady blood sugar. They are not interchangeable products, though, and the difference matters:

• Ozempic is licensed for type 2 diabetes and titrates up to a maximum of 2.0 mg weekly.
• Wegovy is licensed for weight management and goes to 2.4 mg weekly — the dose the major weight-loss trials actually studied.
• Rybelsus is semaglutide as a daily tablet.

So if your goal is weight loss, Ozempic is the off-label route to a lower dose of the same drug. That is worth knowing before you go looking for it specifically.

Branded Ozempic sits above generic semaglutide on price. The bigger change is what happened around it: semaglutide's Indian patent expired on 20 March 2026, more than 40 generic versions launched within weeks at roughly ₹1,300–₹4,200 per month, and branded Wegovy was cut by up to 48% in response.

The practical consequence is that paying a branded premium for a diabetes-licensed product in order to lose weight is now the most expensive way to take semaglutide. Prices move constantly by manufacturer and dose — confirm current numbers during a consultation rather than trusting a listing price.

The headline figure people quote — roughly 15% of body weight over 68 weeks — comes from the STEP 1 trial, which used 2.4 mg semaglutide alongside lifestyle support. That is the Wegovy dose, not Ozempic's 2.0 mg ceiling. Expect somewhat less at a lower dose.

Semaglutide also has cardiovascular evidence behind it: in the SELECT trial, adults with overweight or obesity and existing cardiovascular disease but not diabetes saw a 20% reduction in major adverse cardiovascular events.

Two caveats that matter more than the percentage. Results depend on dose, consistency and habits, and individual outcomes vary widely. And weight regain after stopping is common — which is why dose, nutrition, protein intake and resistance training need to be planned together rather than treated as a medication decision.

Semaglutide is titrated slowly and deliberately. Starting at a full dose is the single most reliable way to make yourself very unwell — the gradual ramp exists to let the gut adapt, not to delay results.

A typical schedule starts at 0.25 mg weekly for four weeks (a tolerance-building dose, not a treatment dose), then steps up roughly every four weeks as tolerated. Your clinician sets the actual steps and the ceiling based on how you respond, your blood sugar and your side effects — see the table below.

Most side effects are digestive, because the drug slows stomach emptying: nausea, vomiting, diarrhoea and constipation. They are typically worst in the first weeks and after each dose increase, and ease for most people within a month or two. Slower titration is the main lever for managing them.

Serious effects are uncommon but real, including pancreatitis and gallbladder problems. Semaglutide carries a boxed warning for thyroid C-cell tumours based on rodent studies, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. It is not for use in pregnancy.

This is exactly why it is a prescription medicine: someone has to screen you for these before you start, not after.

No. Semaglutide is a Schedule H prescription medicine in India, regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940. It can only be dispensed against a valid prescription from a registered medical practitioner.

Treat any seller offering it without one as unsafe on principle — you cannot verify the molecule, the dose or the cold chain, and unapproved compounded “semaglutide” has no quality guarantee behind it.